Big Buttons

• FDA doubles down: Tirzepatide is off shortage

  ...but that doesn't mean the issue is completely settled. read more →

• A couple of state updates

  Good news from Alabama, but a problem in Massachusetts read more →

• Defending GLP-1 compounding

  The latest letters APC's been sending to oppose efforts to restrict compounding read more →

• Thumbs-up for FDA crackdown

  APC was thrilled when the FDA announced it was taking action against illegal online businesses claiming to sell “research-grade” compounds. read more →

• A PANS/PANDAS explainer

  For your patients: Information about a couple of underdiagnosed pediatric mental health conditions read more →

• What, a year?

  In the final board chair column of the year, here are our top 7 accomplishments in 2024. read more →

• “Simply not a rational approach to regulating an industry”

  This week APC offered its final (and pointed) suggestions to the California Board of Pharmacy on their proposed significant – and we would say unjustified – changes to their compounding regulations. read more →

• Get a cease and desist letter from Verrica?

  APC has heard reports from several pharmacies that have received them — here's what to know. read more →

More News

Compounders on Capitol Hill 2023 is coming in hot, with less than three weeks to go. Thus far we’ve thrown plenty of good reasons at you for taking two days in September to fly to Washington DC and make a case for pharmacy compounding to your members of Congress.

But as our Board Chair’s column above makes clear, there’s one reason that trumps all the others: Advocating for your business on Capitol Hill is political insurance. 

It’s how you protect your investment in your pharmacy or facility. It’s how you protect the jobs of those who you employ. It’s how you protect your ability to earn a living.

We need you with us on September 19-20. And so does your pharmacy.

Time is running out. Get registered: